##gff-version 3								
##gvf-version 1.10								
##species https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
NC_045512.2	.	snp	241	241	.	+	.	ID=ID_0;Name=g.C-25T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C-25T;aa_name=;hgvs_nt=NC_045512.2:g.25C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	478	478	.	+	.	ID=ID_1;Name=I71I;alias=I71I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=721;ao=29;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C213T;aa_name=p.I71I;hgvs_nt=NC_045512.2:g.213C>T;hgvs_aa=YP_009724389.1:p.Ile71Ile;hgvs_alias=YP_009724389.1:Ile71Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03866666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	519	519	.	+	.	ID=ID_2;Name=M85T;alias=M85T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=741;ao=7;dp=748;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T254C;aa_name=p.M85T;hgvs_nt=NC_045512.2:g.254T>C;hgvs_aa=YP_009724389.1:p.Met85Thr;hgvs_alias=YP_009724389.1:Met85Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009358288770053475;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	544	544	.	+	.	ID=ID_3;Name=E93D;alias=E93D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=734;ao=16;dp=750;sample_size=777;Reference_seq=A;Variant_seq=C;nt_name=g.A279C;aa_name=p.E93D;hgvs_nt=NC_045512.2:g.279A>C;hgvs_aa=YP_009724389.1:p.Glu93Asp;hgvs_alias=YP_009724389.1:Glu93Asp;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	619	619	.	+	.	ID=ID_4;Name=Y118Y;alias=Y118Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=720;ao=30;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C354T;aa_name=p.Y118Y;hgvs_nt=NC_045512.2:g.354C>T;hgvs_aa=YP_009724389.1:p.Tyr118Tyr;hgvs_alias=YP_009724389.1:Tyr118Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	673	673	.	+	.	ID=ID_5;Name=Y136Y;alias=Y136Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=744;ao=5;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C408T;aa_name=p.Y136Y;hgvs_nt=NC_045512.2:g.408C>T;hgvs_aa=YP_009724389.1:p.Tyr136Tyr;hgvs_alias=YP_009724389.1:Tyr136Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006675567423230975;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	751	751	.	+	.	ID=ID_6;Name=N162N;alias=N162N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=744;ao=6;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C486T;aa_name=p.N162N;hgvs_nt=NC_045512.2:g.486C>T;hgvs_aa=YP_009724389.1:p.Asn162Asn;hgvs_alias=YP_009724389.1:Asn162Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1059	1059	.	+	.	ID=ID_7;Name=T265I;alias=T85I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C794T;aa_name=p.T265I;hgvs_nt=NC_045512.2:g.794C>T;hgvs_aa=YP_009724389.1:p.Thr265Ile;hgvs_alias=YP_009724389.1:Thr85Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1188	1188	.	+	.	ID=ID_8;Name=S308L;alias=S128L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C923T;aa_name=p.S308L;hgvs_nt=NC_045512.2:g.923C>T;hgvs_aa=YP_009724389.1:p.Ser308Leu;hgvs_alias=YP_009724389.1:Ser128Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1376	1376	.	+	.	ID=ID_9;Name=P371S;alias=P191S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=735;ao=15;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C1111T;aa_name=p.P371S;hgvs_nt=NC_045512.2:g.1111C>T;hgvs_aa=YP_009724389.1:p.Pro371Ser;hgvs_alias=YP_009724389.1:Pro191Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1457	1457	.	+	.	ID=ID_10;Name=R398C;alias=R218C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=247;ao=503;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C1192T;aa_name=p.R398C;hgvs_nt=NC_045512.2:g.1192C>T;hgvs_aa=YP_009724389.1:p.Arg398Cys;hgvs_alias=YP_009724389.1:Arg218Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6706666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1593	1593	.	+	.	ID=ID_11;Name=S443F;alias=S263F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=745;ao=5;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C1328T;aa_name=p.S443F;hgvs_nt=NC_045512.2:g.1328C>T;hgvs_aa=YP_009724389.1:p.Ser443Phe;hgvs_alias=YP_009724389.1:Ser263Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1616	1616	.	+	.	ID=ID_12;Name=L451I;alias=L271I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=737;ao=13;dp=750;sample_size=777;Reference_seq=C;Variant_seq=A;nt_name=g.C1351A;aa_name=p.L451I;hgvs_nt=NC_045512.2:g.1351C>A;hgvs_aa=YP_009724389.1:p.Leu451Ile;hgvs_alias=YP_009724389.1:Leu271Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1912	1912	.	+	.	ID=ID_13;Name=S549S;alias=S369S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=742;ao=8;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C1647T;aa_name=p.S549S;hgvs_nt=NC_045512.2:g.1647C>T;hgvs_aa=YP_009724389.1:p.Ser549Ser;hgvs_alias=YP_009724389.1:Ser369Ser;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010666666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2035	2035	.	+	.	ID=ID_14;Name=L590L;alias=L410L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=745;ao=5;dp=750;sample_size=777;Reference_seq=G;Variant_seq=A;nt_name=g.G1770A;aa_name=p.L590L;hgvs_nt=NC_045512.2:g.1770G>A;hgvs_aa=YP_009724389.1:p.Leu590Leu;hgvs_alias=YP_009724389.1:Leu410Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2144	2144	.	+	.	ID=ID_15;Name=V627F;alias=V447F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=724;ao=25;dp=749;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G1879T;aa_name=p.V627F;hgvs_nt=NC_045512.2:g.1879G>T;hgvs_aa=YP_009724389.1:p.Val627Phe;hgvs_alias=YP_009724389.1:Val447Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03337783711615487;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2232	2232	.	+	.	ID=ID_16;Name=A656V;alias=A476V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=739;ao=11;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C1967T;aa_name=p.A656V;hgvs_nt=NC_045512.2:g.1967C>T;hgvs_aa=YP_009724389.1:p.Ala656Val;hgvs_alias=YP_009724389.1:Ala476Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014666666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2354	2354	.	+	.	ID=ID_17;Name=G697R;alias=G517R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=745;ao=5;dp=750;sample_size=777;Reference_seq=G;Variant_seq=A;nt_name=g.G2089A;aa_name=p.G697R;hgvs_nt=NC_045512.2:g.2089G>A;hgvs_aa=YP_009724389.1:p.Gly697Arg;hgvs_alias=YP_009724389.1:Gly517Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2395	2395	.	+	.	ID=ID_18;Name=V710V;alias=V530V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C2130T;aa_name=p.V710V;hgvs_nt=NC_045512.2:g.2130C>T;hgvs_aa=YP_009724389.1:p.Val710Val;hgvs_alias=YP_009724389.1:Val530Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2406	2406	.	+	.	ID=ID_19;Name=K714R;alias=K534R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A2141G;aa_name=p.K714R;hgvs_nt=NC_045512.2:g.2141A>G;hgvs_aa=YP_009724389.1:p.Lys714Arg;hgvs_alias=YP_009724389.1:Lys534Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2597	2597	.	+	.	ID=ID_20;Name=L778L;alias=L598L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T2332C;aa_name=p.L778L;hgvs_nt=NC_045512.2:g.2332T>C;hgvs_aa=YP_009724389.1:p.Leu778Leu;hgvs_alias=YP_009724389.1:Leu598Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2695	2695	.	+	.	ID=ID_21;Name=N810N;alias=N630N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=736;ao=14;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C2430T;aa_name=p.N810N;hgvs_nt=NC_045512.2:g.2430C>T;hgvs_aa=YP_009724389.1:p.Asn810Asn;hgvs_alias=YP_009724389.1:Asn630Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.018666666666666668;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2747	2747	.	+	.	ID=ID_22;Name=D828Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=729;ao=21;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G2482T;aa_name=p.D828Y;hgvs_nt=NC_045512.2:g.2482G>T;hgvs_aa=YP_009724389.1:p.Asp828Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.028;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2878	2878	.	+	.	ID=ID_23;Name=F871F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=698;ao=52;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C2613T;aa_name=p.F871F;hgvs_nt=NC_045512.2:g.2613C>T;hgvs_aa=YP_009724389.1:p.Phe871Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06933333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2930	2930	.	+	.	ID=ID_24;Name=L889L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=743;ao=7;dp=750;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T2665C;aa_name=p.L889L;hgvs_nt=NC_045512.2:g.2665T>C;hgvs_aa=YP_009724389.1:p.Leu889Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3037	3037	.	+	.	ID=ID_25;Name=F924F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C2772T;aa_name=p.F924F;hgvs_nt=NC_045512.2:g.2772C>T;hgvs_aa=YP_009724389.1:p.Phe924Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3241	3241	.	+	.	ID=ID_26;Name=D992D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=718;ao=32;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C2976T;aa_name=p.D992D;hgvs_nt=NC_045512.2:g.2976C>T;hgvs_aa=YP_009724389.1:p.Asp992Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.042666666666666665;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3330	3330	.	+	.	ID=ID_27;Name=T1022I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=744;ao=6;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C3065T;aa_name=p.T1022I;hgvs_nt=NC_045512.2:g.3065C>T;hgvs_aa=YP_009724389.1:p.Thr1022Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3620	3620	.	+	.	ID=ID_28;Name=G1119S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=741;ao=8;dp=749;sample_size=777;Reference_seq=G;Variant_seq=A;nt_name=g.G3355A;aa_name=p.G1119S;hgvs_nt=NC_045512.2:g.3355G>A;hgvs_aa=YP_009724389.1:p.Gly1119Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010680907877169559;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3842	3842	.	+	.	ID=ID_29;Name=M1193V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=720;ao=29;dp=749;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A3577G;aa_name=p.M1193V;hgvs_nt=NC_045512.2:g.3577A>G;hgvs_aa=YP_009724389.1:p.Met1193Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03871829105473965;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3879	3879	.	+	.	ID=ID_30;Name=E1205A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=252;ao=497;dp=749;sample_size=777;Reference_seq=A;Variant_seq=C;nt_name=g.A3614C;aa_name=p.E1205A;hgvs_nt=NC_045512.2:g.3614A>C;hgvs_aa=YP_009724389.1:p.Glu1205Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6635514018691588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3903	3903	.	+	.	ID=ID_31;Name=P1213L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=722;ao=27;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C3638T;aa_name=p.P1213L;hgvs_nt=NC_045512.2:g.3638C>T;hgvs_aa=YP_009724389.1:p.Pro1213Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.036048064085447265;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4158	4158	.	+	.	ID=ID_32;Name=A1298V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=743;ao=6;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C3893T;aa_name=p.A1298V;hgvs_nt=NC_045512.2:g.3893C>T;hgvs_aa=YP_009724389.1:p.Ala1298Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00801068090787717;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4160	4160	.	+	.	ID=ID_33;Name=V1299L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=745;ao=4;dp=749;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G3895T;aa_name=p.V1299L;hgvs_nt=NC_045512.2:g.3895G>T;hgvs_aa=YP_009724389.1:p.Val1299Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053404539385847796;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4296	4296	.	+	.	ID=ID_34;Name=T1344K;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=744;ao=6;dp=750;sample_size=777;Reference_seq=C;Variant_seq=A;nt_name=g.C4031A;aa_name=p.T1344K;hgvs_nt=NC_045512.2:g.4031C>A;hgvs_aa=YP_009724389.1:p.Thr1344Lys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4543	4543	.	+	.	ID=ID_35;Name=T1426T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C4278T;aa_name=p.T1426T;hgvs_nt=NC_045512.2:g.4278C>T;hgvs_aa=YP_009724389.1:p.Thr1426Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4655	4655	.	+	.	ID=ID_36;Name=R1464W;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=736;ao=13;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C4390T;aa_name=p.R1464W;hgvs_nt=NC_045512.2:g.4390C>T;hgvs_aa=YP_009724389.1:p.Arg1464Trp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017356475300400534;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4668	4668	.	+	.	ID=ID_37;Name=S1468F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=745;ao=4;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C4403T;aa_name=p.S1468F;hgvs_nt=NC_045512.2:g.4403C>T;hgvs_aa=YP_009724389.1:p.Ser1468Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053404539385847796;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4782	4782	.	+	.	ID=ID_38;Name=S1506L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=720;ao=29;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C4517T;aa_name=p.S1506L;hgvs_nt=NC_045512.2:g.4517C>T;hgvs_aa=YP_009724389.1:p.Ser1506Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03871829105473965;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5365	5365	.	+	.	ID=ID_39;Name=Y1700Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C5100T;aa_name=p.Y1700Y;hgvs_nt=NC_045512.2:g.5100C>T;hgvs_aa=YP_009724389.1:p.Tyr1700Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5780	5780	.	+	.	ID=ID_40;Name=I1839V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=745;ao=4;dp=749;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A5515G;aa_name=p.I1839V;hgvs_nt=NC_045512.2:g.5515A>G;hgvs_aa=YP_009724389.1:p.Ile1839Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053404539385847796;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5857	5857	.	+	.	ID=ID_41;Name=T1864T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=698;ao=52;dp=750;sample_size=777;Reference_seq=G;Variant_seq=A;nt_name=g.G5592A;aa_name=p.T1864T;hgvs_nt=NC_045512.2:g.5592G>A;hgvs_aa=YP_009724389.1:p.Thr1864Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06933333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6255	6255	.	+	.	ID=ID_42;Name=A1997V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=719;ao=30;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C5990T;aa_name=p.A1997V;hgvs_nt=NC_045512.2:g.5990C>T;hgvs_aa=YP_009724389.1:p.Ala1997Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04005340453938585;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6449	6449	.	+	.	ID=ID_43;Name=L2062F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=744;ao=6;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C6184T;aa_name=p.L2062F;hgvs_nt=NC_045512.2:g.6184C>T;hgvs_aa=YP_009724389.1:p.Leu2062Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6573	6573	.	+	.	ID=ID_44;Name=S2103F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=745;ao=4;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C6308T;aa_name=p.S2103F;hgvs_nt=NC_045512.2:g.6308C>T;hgvs_aa=YP_009724389.1:p.Ser2103Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053404539385847796;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6633	6633	.	+	.	ID=ID_45;Name=A2123V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=737;ao=12;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C6368T;aa_name=p.A2123V;hgvs_nt=NC_045512.2:g.6368C>T;hgvs_aa=YP_009724389.1:p.Ala2123Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01602136181575434;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7267	7267	.	+	.	ID=ID_46;Name=F2334F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=725;ao=22;dp=747;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C7002T;aa_name=p.F2334F;hgvs_nt=NC_045512.2:g.7002C>T;hgvs_aa=YP_009724389.1:p.Phe2334Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.029451137884872823;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7479	7479	.	+	.	ID=ID_47;Name=N2405S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=740;ao=10;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A7214G;aa_name=p.N2405S;hgvs_nt=NC_045512.2:g.7214A>G;hgvs_aa=YP_009724389.1:p.Asn2405Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7528	7528	.	+	.	ID=ID_48;Name=V2421V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C7263T;aa_name=p.V2421V;hgvs_nt=NC_045512.2:g.7263C>T;hgvs_aa=YP_009724389.1:p.Val2421Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7675	7675	.	+	.	ID=ID_49;Name=A2470A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=698;ao=52;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G7410T;aa_name=p.A2470A;hgvs_nt=NC_045512.2:g.7410G>T;hgvs_aa=YP_009724389.1:p.Ala2470Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06933333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7732	7732	.	+	.	ID=ID_50;Name=Y2489Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=745;ao=5;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C7467T;aa_name=p.Y2489Y;hgvs_nt=NC_045512.2:g.7467C>T;hgvs_aa=YP_009724389.1:p.Tyr2489Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7945	7945	.	+	.	ID=ID_51;Name=Y2560Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C7680T;aa_name=p.Y2560Y;hgvs_nt=NC_045512.2:g.7680C>T;hgvs_aa=YP_009724389.1:p.Tyr2560Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8290	8290	.	+	.	ID=ID_52;Name=L2675L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=744;ao=6;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C8025T;aa_name=p.L2675L;hgvs_nt=NC_045512.2:g.8025C>T;hgvs_aa=YP_009724389.1:p.Leu2675Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8947	8947	.	+	.	ID=ID_53;Name=N2894N;alias=N131N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=4;ao=746;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C8682T;aa_name=p.N2894N;hgvs_nt=NC_045512.2:g.8682C>T;hgvs_aa=YP_009724389.1:p.Asn2894Asn;hgvs_alias=YP_009724389.1:Asn131Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9946666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9245	9245	.	+	.	ID=ID_54;Name=A2994T;alias=A231T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=739;ao=11;dp=750;sample_size=777;Reference_seq=G;Variant_seq=A;nt_name=g.G8980A;aa_name=p.A2994T;hgvs_nt=NC_045512.2:g.8980G>A;hgvs_aa=YP_009724389.1:p.Ala2994Thr;hgvs_alias=YP_009724389.1:Ala231Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014666666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9286	9286	.	+	.	ID=ID_55;Name=N3007N;alias=N244N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=612;ao=137;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C9021T;aa_name=p.N3007N;hgvs_nt=NC_045512.2:g.9021C>T;hgvs_aa=YP_009724389.1:p.Asn3007Asn;hgvs_alias=YP_009724389.1:Asn244Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1829105473965287;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9661	9661	.	+	.	ID=ID_56;Name=F3132F;alias=F369F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C9396T;aa_name=p.F3132F;hgvs_nt=NC_045512.2:g.9396C>T;hgvs_aa=YP_009724389.1:p.Phe3132Phe;hgvs_alias=YP_009724389.1:Phe369Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9803	9803	.	+	.	ID=ID_57;Name=L3180L;alias=L417L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=742;ao=8;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C9538T;aa_name=p.L3180L;hgvs_nt=NC_045512.2:g.9538C>T;hgvs_aa=YP_009724389.1:p.Leu3180Leu;hgvs_alias=YP_009724389.1:Leu417Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010666666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10246	10246	.	+	.	ID=ID_58;Name=H3327H;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=725;ao=25;dp=750;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T9981C;aa_name=p.H3327H;hgvs_nt=NC_045512.2:g.9981T>C;hgvs_aa=YP_009724389.1:p.His3327His;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10401	10401	.	+	.	ID=ID_59;Name=A3379V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=721;ao=29;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C10136T;aa_name=p.A3379V;hgvs_nt=NC_045512.2:g.10136C>T;hgvs_aa=YP_009724389.1:p.Ala3379Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03866666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10444	10444	.	+	.	ID=ID_60;Name=M3393I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=744;ao=6;dp=750;sample_size=777;Reference_seq=G;Variant_seq=A;nt_name=g.G10179A;aa_name=p.M3393I;hgvs_nt=NC_045512.2:g.10179G>A;hgvs_aa=YP_009724389.1:p.Met3393Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10450	10450	.	+	.	ID=ID_61;Name=P3395P;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=720;ao=30;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C10185T;aa_name=p.P3395P;hgvs_nt=NC_045512.2:g.10185C>T;hgvs_aa=YP_009724389.1:p.Pro3395Pro;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10641	10641	.	+	.	ID=ID_62;Name=T3459M;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=737;ao=13;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C10376T;aa_name=p.T3459M;hgvs_nt=NC_045512.2:g.10376C>T;hgvs_aa=YP_009724389.1:p.Thr3459Met;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10777	10777	.	+	.	ID=ID_63;Name=P3504P;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=717;ao=33;dp=750;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T10512C;aa_name=p.P3504P;hgvs_nt=NC_045512.2:g.10512T>C;hgvs_aa=YP_009724389.1:p.Pro3504Pro;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11020	11020	.	+	.	ID=ID_64;Name=L3585L;alias=L16L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=745;ao=5;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C10755T;aa_name=p.L3585L;hgvs_nt=NC_045512.2:g.10755C>T;hgvs_aa=YP_009724389.1:p.Leu3585Leu;hgvs_alias=YP_009724389.1:Leu16Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11083	11083	.	+	.	ID=ID_65;Name=L3606F;alias=L37F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=740;ao=9;dp=749;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G10818T;aa_name=p.L3606F;hgvs_nt=NC_045512.2:g.10818G>T;hgvs_aa=YP_009724389.1:p.Leu3606Phe;hgvs_alias=YP_009724389.1:Leu37Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012016021361815754;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11335	11335	.	+	.	ID=ID_66;Name=V3690V;alias=V121V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=743;ao=5;dp=748;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G11070T;aa_name=p.V3690V;hgvs_nt=NC_045512.2:g.11070G>T;hgvs_aa=YP_009724389.1:p.Val3690Val;hgvs_alias=YP_009724389.1:Val121Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066844919786096255;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11417	11417	.	+	.	ID=ID_67;Name=V3718F;alias=V149F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G11152T;aa_name=p.V3718F;hgvs_nt=NC_045512.2:g.11152G>T;hgvs_aa=YP_009724389.1:p.Val3718Phe;hgvs_alias=YP_009724389.1:Val149Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11747	11747	.	+	.	ID=ID_68;Name=L3828L;alias=L259L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=745;ao=5;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C11482T;aa_name=p.L3828L;hgvs_nt=NC_045512.2:g.11482C>T;hgvs_aa=YP_009724389.1:p.Leu3828Leu;hgvs_alias=YP_009724389.1:Leu259Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12053	12053	.	+	.	ID=ID_69;Name=L3930F;alias=L71F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3860..3942;ro=706;ao=44;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C11788T;aa_name=p.L3930F;hgvs_nt=NC_045512.2:g.11788C>T;hgvs_aa=YP_009724389.1:p.Leu3930Phe;hgvs_alias=YP_009724389.1:Leu71Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.058666666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12084	12084	.	+	.	ID=ID_70;Name=T3940I;alias=T81I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3860..3942;ro=739;ao=10;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C11819T;aa_name=p.T3940I;hgvs_nt=NC_045512.2:g.11819C>T;hgvs_aa=YP_009724389.1:p.Thr3940Ile;hgvs_alias=YP_009724389.1:Thr81Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01335113484646195;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12100	12100	.	+	.	ID=ID_71;Name=A3945A;alias=A3A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=4;ao=746;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C11835T;aa_name=p.A3945A;hgvs_nt=NC_045512.2:g.11835C>T;hgvs_aa=YP_009724389.1:p.Ala3945Ala;hgvs_alias=YP_009724389.1:Ala3Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9946666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12242	12242	.	+	.	ID=ID_72;Name=R3993C;alias=R51C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=744;ao=6;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C11977T;aa_name=p.R3993C;hgvs_nt=NC_045512.2:g.11977C>T;hgvs_aa=YP_009724389.1:p.Arg3993Cys;hgvs_alias=YP_009724389.1:Arg51Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12400	12400	.	+	.	ID=ID_73;Name=L4045L;alias=L103L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=740;ao=10;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C12135T;aa_name=p.L4045L;hgvs_nt=NC_045512.2:g.12135C>T;hgvs_aa=YP_009724389.1:p.Leu4045Leu;hgvs_alias=YP_009724389.1:Leu103Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12878	12878	.	+	.	ID=ID_74;Name=I4205V;alias=I65V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A12613G;aa_name=p.I4205V;hgvs_nt=NC_045512.2:g.12613A>G;hgvs_aa=YP_009724389.1:p.Ile4205Val;hgvs_alias=YP_009724389.1:Ile65Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12970	12970	.	+	.	ID=ID_75;Name=N4235N;alias=N95N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=698;ao=52;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C12705T;aa_name=p.N4235N;hgvs_nt=NC_045512.2:g.12705C>T;hgvs_aa=YP_009724389.1:p.Asn4235Asn;hgvs_alias=YP_009724389.1:Asn95Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06933333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13249	13249	.	+	.	ID=ID_76;Name=L4328L;alias=L75L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp10;mat_pep_desc=nsp10_CysHis%3B formerly known as growth-factor-like protein (GFL)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4254..4392;ro=738;ao=12;dp=750;sample_size=777;Reference_seq=G;Variant_seq=A;nt_name=g.G12984A;aa_name=p.L4328L;hgvs_nt=NC_045512.2:g.12984G>A;hgvs_aa=YP_009724389.1:p.Leu4328Leu;hgvs_alias=YP_009724389.1:Leu75Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13261	13261	.	+	.	ID=ID_77;Name=C4332C;alias=C79C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp10;mat_pep_desc=nsp10_CysHis%3B formerly known as growth-factor-like protein (GFL)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4254..4392;ro=721;ao=29;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C12996T;aa_name=p.C4332C;hgvs_nt=NC_045512.2:g.12996C>T;hgvs_aa=YP_009724389.1:p.Cys4332Cys;hgvs_alias=YP_009724389.1:Cys79Cys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03866666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13350	13350	.	+	.	ID=ID_78;Name=G4362V;alias=G109V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp10;mat_pep_desc=nsp10_CysHis%3B formerly known as growth-factor-like protein (GFL)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4254..4392;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G13085T;aa_name=p.G4362V;hgvs_nt=NC_045512.2:g.13085G>T;hgvs_aa=YP_009724389.1:p.Gly4362Val;hgvs_alias=YP_009724389.1:Gly109Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13712	13712	.	+	.	ID=ID_79;Name=K4483R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=743;ao=7;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A13448G;aa_name=p.K4483R;hgvs_nt=NC_045512.2:g.13448A>G;hgvs_aa=YP_009724389.1:p.Lys4483Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14256	14256	.	+	.	ID=ID_80;Name=K4664K;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=743;ao=7;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A13992G;aa_name=p.K4664K;hgvs_nt=NC_045512.2:g.13992A>G;hgvs_aa=YP_009724389.1:p.Lys4664Lys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14335	14335	.	+	.	ID=ID_81;Name=V4691I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=G;Variant_seq=A;nt_name=g.G14071A;aa_name=p.V4691I;hgvs_nt=NC_045512.2:g.14071G>A;hgvs_aa=YP_009724389.1:p.Val4691Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14408	14408	.	+	.	ID=ID_82;Name=P4715L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C14144T;aa_name=p.P4715L;hgvs_nt=NC_045512.2:g.14144C>T;hgvs_aa=YP_009724389.1:p.Pro4715Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14625	14625	.	+	.	ID=ID_83;Name=C4787C;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=724;ao=26;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C14361T;aa_name=p.C4787C;hgvs_nt=NC_045512.2:g.14361C>T;hgvs_aa=YP_009724389.1:p.Cys4787Cys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.034666666666666665;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14786	14786	.	+	.	ID=ID_84;Name=A4841V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=740;ao=10;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C14522T;aa_name=p.A4841V;hgvs_nt=NC_045512.2:g.14522C>T;hgvs_aa=YP_009724389.1:p.Ala4841Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15452	15452	.	+	.	ID=ID_85;Name=G5063V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G15188T;aa_name=p.G5063V;hgvs_nt=NC_045512.2:g.15188G>T;hgvs_aa=YP_009724389.1:p.Gly5063Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15540	15540	.	+	.	ID=ID_86;Name=V5092V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=703;ao=47;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C15276T;aa_name=p.V5092V;hgvs_nt=NC_045512.2:g.15276C>T;hgvs_aa=YP_009724389.1:p.Val5092Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06266666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15589	15589	.	+	.	ID=ID_87;Name=D5109N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=744;ao=6;dp=750;sample_size=777;Reference_seq=G;Variant_seq=A;nt_name=g.G15325A;aa_name=p.D5109N;hgvs_nt=NC_045512.2:g.15325G>A;hgvs_aa=YP_009724389.1:p.Asp5109Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15720	15720	.	+	.	ID=ID_88;Name=D5152D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=738;ao=12;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C15456T;aa_name=p.D5152D;hgvs_nt=NC_045512.2:g.15456C>T;hgvs_aa=YP_009724389.1:p.Asp5152Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16523	16523	.	+	.	ID=ID_89;Name=T5420I;alias=T96I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=745;ao=5;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C16259T;aa_name=p.T5420I;hgvs_nt=NC_045512.2:g.16259C>T;hgvs_aa=YP_009724389.1:p.Thr5420Ile;hgvs_alias=YP_009724389.1:Thr96Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16638	16638	.	+	.	ID=ID_90;Name=A5458A;alias=A134A;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=743;ao=7;dp=750;sample_size=777;Reference_seq=A;Variant_seq=T;nt_name=g.A16374T;aa_name=p.A5458A;hgvs_nt=NC_045512.2:g.16374A>T;hgvs_aa=YP_009724389.1:p.Ala5458Ala;hgvs_alias=YP_009724389.1:Ala134Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16687	16687	.	+	.	ID=ID_91;Name=I5475V;alias=I151V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=743;ao=4;dp=747;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A16423G;aa_name=p.I5475V;hgvs_nt=NC_045512.2:g.16423A>G;hgvs_aa=YP_009724389.1:p.Ile5475Val;hgvs_alias=YP_009724389.1:Ile151Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00535475234270415;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16852	16852	.	+	.	ID=ID_92;Name=G5530C;alias=G206C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=745;ao=4;dp=749;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G16588T;aa_name=p.G5530C;hgvs_nt=NC_045512.2:g.16588G>T;hgvs_aa=YP_009724389.1:p.Gly5530Cys;hgvs_alias=YP_009724389.1:Gly206Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053404539385847796;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16945	16945	.	+	.	ID=ID_93;Name=A5561S;alias=A237S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=728;ao=22;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G16681T;aa_name=p.A5561S;hgvs_nt=NC_045512.2:g.16681G>T;hgvs_aa=YP_009724389.1:p.Ala5561Ser;hgvs_alias=YP_009724389.1:Ala237Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.029333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	17010	17010	.	+	.	ID=ID_94;Name=D5584Y;alias=D260Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=25;dp=749;sample_size=777;Reference_seq=CTCAG;Variant_seq=TTCAT;nt_name=g.CTCAG16746_16750TTCAT;aa_name=p.D5584Y;hgvs_nt=n/a;hgvs_aa=YP_009724389.1:p.Asp5584Tyr;hgvs_alias=YP_009724389.1:Asp260Tyr;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03337783711615487;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17010	17010	.	+	.	ID=ID_94;Name=D5584Y;alias=D260Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=724;dp=749;sample_size=777;Reference_seq=CTCAG;Variant_seq=CTCAT;nt_name=g.G16750T;aa_name=p.D5584Y;hgvs_nt=NC_045512.2:g.16750G>T;hgvs_aa=YP_009724389.1:p.Asp5584Tyr;hgvs_alias=YP_009724389.1:Asp260Tyr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9666221628838452;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17615	17615	.	+	.	ID=ID_95;Name=K5784R;alias=K460R;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=706;ao=44;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A17351G;aa_name=p.K5784R;hgvs_nt=NC_045512.2:g.17351A>G;hgvs_aa=YP_009724389.1:p.Lys5784Arg;hgvs_alias=YP_009724389.1:Lys460Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.058666666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17811	17811	.	+	.	ID=ID_96;Name=I5849I;alias=I525I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=556;ao=194;dp=750;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T17547C;aa_name=p.I5849I;hgvs_nt=NC_045512.2:g.17547T>C;hgvs_aa=YP_009724389.1:p.Ile5849Ile;hgvs_alias=YP_009724389.1:Ile525Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.25866666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17818	17818	.	+	.	ID=ID_97;Name=L5852L;alias=L528L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C17554T;aa_name=p.L5852L;hgvs_nt=NC_045512.2:g.17554C>T;hgvs_aa=YP_009724389.1:p.Leu5852Leu;hgvs_alias=YP_009724389.1:Leu528Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18148	18148	.	+	.	ID=ID_98;Name=G5962C;alias=G37C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G17884T;aa_name=p.G5962C;hgvs_nt=NC_045512.2:g.17884G>T;hgvs_aa=YP_009724389.1:p.Gly5962Cys;hgvs_alias=YP_009724389.1:Gly37Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18223	18223	.	+	.	ID=ID_99;Name=M5987V;alias=M62V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=744;ao=6;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A17959G;aa_name=p.M5987V;hgvs_nt=NC_045512.2:g.17959A>G;hgvs_aa=YP_009724389.1:p.Met5987Val;hgvs_alias=YP_009724389.1:Met62Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	18895	18895	.	+	.	ID=ID_100;Name=V6212F;alias=V287F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=710;ao=30;dp=749;sample_size=777;Reference_seq=TTTG;Variant_seq=T;nt_name=g.G18634T;aa_name=p.V6212F;hgvs_nt=NC_045512.2:g.18634G>T;hgvs_aa=YP_009724389.1:p.Val6212Phe;hgvs_alias=YP_009724389.1:Val287Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04005340453938585;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18895	18895	.	+	.	ID=ID_101;Name=V6212del;alias=V287del;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=710;ao=9;dp=749;sample_size=777;Reference_seq=TTTG;Variant_seq=TTTT;nt_name=g.18634_18636delGTT;aa_name=p.V6212del;hgvs_nt=NC_045512.2:g.18634_18636del;hgvs_aa=YP_009724389.1:p.Val6212del;hgvs_alias=YP_009724389.1:Val287del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012016021361815754;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19269	19269	.	+	.	ID=ID_102;Name=N6335N;alias=N410N;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=678;ao=72;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C19005T;aa_name=p.N6335N;hgvs_nt=NC_045512.2:g.19005C>T;hgvs_aa=YP_009724389.1:p.Asn6335Asn;hgvs_alias=YP_009724389.1:Asn410Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.096;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19524	19524	.	+	.	ID=ID_103;Name=L6420L;alias=L495L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=731;ao=14;dp=745;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C19260T;aa_name=p.L6420L;hgvs_nt=NC_045512.2:g.19260C>T;hgvs_aa=YP_009724389.1:p.Leu6420Leu;hgvs_alias=YP_009724389.1:Leu495Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01879194630872483;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19791	19791	.	+	.	ID=ID_104;Name=L6509L;alias=L57L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T19527G;aa_name=p.L6509L;hgvs_nt=NC_045512.2:g.19527T>G;hgvs_aa=YP_009724389.1:p.Leu6509Leu;hgvs_alias=YP_009724389.1:Leu57Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21110	21110	.	+	.	ID=ID_105;Name=T6949I;alias=T151I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=735;ao=12;dp=747;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C20846T;aa_name=p.T6949I;hgvs_nt=NC_045512.2:g.20846C>T;hgvs_aa=YP_009724389.1:p.Thr6949Ile;hgvs_alias=YP_009724389.1:Thr151Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01606425702811245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21304	21304	.	+	.	ID=ID_106;Name=R7014C;alias=R216C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=731;ao=15;dp=746;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C21040T;aa_name=p.R7014C;hgvs_nt=NC_045512.2:g.21040C>T;hgvs_aa=YP_009724389.1:p.Arg7014Cys;hgvs_alias=YP_009724389.1:Arg216Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.020107238605898123;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21306	21306	.	+	.	ID=ID_107;Name=R7014R;alias=R216R;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=740;ao=7;dp=747;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C21042T;aa_name=p.R7014R;hgvs_nt=NC_045512.2:g.21042C>T;hgvs_aa=YP_009724389.1:p.Arg7014Arg;hgvs_alias=YP_009724389.1:Arg216Arg;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009370816599732263;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21431	21431	.	+	.	ID=ID_108;Name=A7056V;alias=A258V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=710;ao=40;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C21167T;aa_name=p.A7056V;hgvs_nt=NC_045512.2:g.21167C>T;hgvs_aa=YP_009724389.1:p.Ala7056Val;hgvs_alias=YP_009724389.1:Ala258Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_109;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=738;ao=11;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014686248331108143;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_109;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=738;ao=11;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014686248331108143;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_109;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=738;ao=11;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014686248331108143;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_110;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=W152C,L452R;function_description=14 of 34 RBD-specific mAbs showed reduced neutralization to the B.1.427/B.1.429 variant pseudotype.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_111;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=The S13I mutation dampened binding of 5 mAbs and abrogated binding of 5 additional mAbs out of 11 neutralizing mAbs evaluated. Predicted to shift the signal peptide cleavage site from S13-Q14 to C15-V16, which can affect NTD conformation.  PG: in saying S12F does not shift the signal peptide nor affect mAb binding, this manuscript appears to contradict the  text of McCallum et al.'s earlier 2021 manuscript stating that S12F *does* affected some mAb binding via putative signal peptide shift.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_112;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=W152C;function_description=The B.1.427/B.1.429 S13I/W152C NTD did not bind to any NTD-directed neutralizing mAbs, which are known to target a single antigenic site (antigenic site i), whereas binding of the non-neutralizing S2L20 mAb to the NTD antigenic site iv was not affected by any mutants, confirming proper retention of folding.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_113;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.42x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_114;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,W152C,L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_110;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=W152C,L452R;function_description=Swab samples N/NP viral RNA is approximately 2-fold higher in B.1.427/B.1.429 than in non-variant viruses.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_110;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=W152C,L452R;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10 convalescent plasma was somewhat poorer (3.1-fold).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_110;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1.full.pdf;citation=McCallum et al. (2021);comb_mutation=W152C,L452R;function_description=In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for B.1.427/B.1.429 compared to wildtype (D614G). In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_110;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=W152C,L452R;function_description=Antibody neutralization assays showed 6.7-fold resistence against 7/8 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_110;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=W152C,L452R;function_description=Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	"ID=ID_110;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1093/cid/ciab283;citation=Peng et al. (2021);comb_mutation=W152C,L452R;function_description=Lineages bearing these spike mutations comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household  contacts exposed to the ""California"" or ""West Coast"" variants (B.1.427 and B.1.429) were at higher risk of infection compared  to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, RR;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_113;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_114;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,W152C,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_110;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=W152C,L452R;function_description=Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was reduced ~2.8-fold compared to wildtype (D614G) S.  It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose).  Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech BNT162b2-elicited plasma neutralizing activity.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_114;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=W152C,L452R,D614G;function_description=Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_114;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=W152C,L452R,D614G;function_description=Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_114;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=W152C,L452R,D614G;function_description=Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_114;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=W152C,L452R,D614G;function_description=6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_113;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_114;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,W152C,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21634	21634	.	+	.	ID=ID_115;Name=L24F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=743;ao=5;dp=748;sample_size=777;Reference_seq=A;Variant_seq=C;nt_name=g.A72C;aa_name=p.L24F;hgvs_nt=NC_045512.2:g.72A>C;hgvs_aa=YP_009724390.1:p.Leu24Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066844919786096255;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_116;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=744;ao=4;dp=748;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053475935828877;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_116;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=744;ao=4;dp=748;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053475935828877;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21638	21638	.	+	.	ID=ID_116;Name=P26S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=744;ao=4;dp=748;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C76T;aa_name=p.P26S;hgvs_nt=NC_045512.2:g.76C>T;hgvs_aa=YP_009724390.1:p.Pro26Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053475935828877;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21691	21691	.	+	.	ID=ID_117;Name=F43F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C129T;aa_name=p.F43F;hgvs_nt=NC_045512.2:g.129C>T;hgvs_aa=YP_009724390.1:p.Phe43Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21844	21844	.	+	.	ID=ID_118;Name=S94S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=707;ao=4;dp=711;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C282T;aa_name=p.S94S;hgvs_nt=NC_045512.2:g.282C>T;hgvs_aa=YP_009724390.1:p.Ser94Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005625879043600563;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21859	21859	.	+	.	ID=ID_119;Name=N99N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=705;ao=8;dp=713;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C297T;aa_name=p.N99N;hgvs_nt=NC_045512.2:g.297C>T;hgvs_aa=YP_009724390.1:p.Asn99Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011220196353436185;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_120;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=690;ao=18;dp=708;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025423728813559324;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_120;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=690;ao=18;dp=708;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025423728813559324;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_121;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=690;ao=18;dp=708;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025423728813559324;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.43 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21974	21974	.	+	.	ID=ID_120;Name=D138Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=690;ao=18;dp=708;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G412T;aa_name=p.D138Y;hgvs_nt=NC_045512.2:g.412G>T;hgvs_aa=YP_009724390.1:p.Asp138Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025423728813559324;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	21980	21980	.	+	.	ID=ID_122;Name=L141_V143del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=692;ao=16;dp=708;sample_size=777;Reference_seq=TTTTTGGGTG;Variant_seq=T;nt_name=g.422_430delTGGGTGTTT;aa_name=p.L141_V143del;hgvs_nt=NC_045512.2:g.422_430del;hgvs_aa=YP_009724390.1:p.Leu141_Val143del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022598870056497175;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_110;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=S13I,L452R;function_description=14 of 34 RBD-specific mAbs showed reduced neutralization to the B.1.427/B.1.429 variant pseudotype.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_123;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=The W152C mutation reduced recognition of six NTD neutralizing mAbs, including a complete loss of binding for two of them, with a complementary pattern to that observed for S13I (also found in lineage B.1.427/B.1.429) out of 11 neutralizing mAbs evaluated.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_112;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=S13I;function_description=The B.1.427/B.1.429 S13I/W152C NTD did not bind to any NTD-directed neutralizing mAbs, which are known to target a single antigenic site (antigenic site i), whereas binding of the non-neutralizing S2L20 mAb to the NTD antigenic site iv was not affected by any mutants, confirming proper retention of folding.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_124;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_114;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_123;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=;function_description=Pseudoviruses carrying the W152C mutation demonstrated small increases in cell entry compared to  D614G alone in 293T cells and human airway organoids.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_110;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,L452R;function_description=Swab samples N/NP viral RNA is approximately 2-fold higher in B.1.427/B.1.429 than in non-variant viruses.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_110;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=S13I,L452R;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10 convalescent plasma was somewhat poorer (3.1-fold).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_110;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1.full.pdf;citation=McCallum et al. (2021);comb_mutation=S13I,L452R;function_description=In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for B.1.427/B.1.429 compared to wildtype (D614G). In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_110;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,L452R;function_description=Antibody neutralization assays showed 6.7-fold resistence against 7/8 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_110;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,L452R;function_description=Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	"ID=ID_110;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1093/cid/ciab283;citation=Peng et al. (2021);comb_mutation=S13I,L452R;function_description=Lineages bearing these spike mutations comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household  contacts exposed to the ""California"" or ""West Coast"" variants (B.1.427 and B.1.429) were at higher risk of infection compared  to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, RR;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_124;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.15x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_114;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_110;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=S13I,L452R;function_description=Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was reduced ~2.8-fold compared to wildtype (D614G) S.  It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose).  Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech BNT162b2-elicited plasma neutralizing activity.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_114;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=S13I,L452R,D614G;function_description=Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_114;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=S13I,L452R,D614G;function_description=Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_114;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=S13I,L452R,D614G;function_description=Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_114;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,L452R,D614G;function_description=6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_124;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.03x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_114;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22227	22227	.	+	.	"ID=ID_125;Name=A222V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=739;ao=11;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C665T;aa_name=p.A222V;hgvs_nt=NC_045512.2:g.665C>T;hgvs_aa=YP_009724390.1:p.Ala222Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014666666666666666;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Not associated with significant reduction of EC50 (recognition) in any antigenic supersite ""i"" monoclonal antibodies.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22227	22227	.	+	.	ID=ID_126;Name=A222V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=739;ao=11;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C665T;aa_name=p.A222V;hgvs_nt=NC_045512.2:g.665C>T;hgvs_aa=YP_009724390.1:p.Ala222Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014666666666666666;function_category=humoral response durability;source=https://dx.doi.org/10.3390%2Fv13040661;citation=Brehm et al. (2021);comb_mutation=D614G;function_description=27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3), i.e. with a  9 month interval. Both cases were mild. No significant differences in the neutralizing capacity of the two linages were observed in 4 sera taken (1 pre-reinfection,  three post-reinfection). Neutralizing antibody titres (IC50) before and immediately after re-infection were <300 against  both strains, and jumped >7x upon re-infection. Viral titres were also higher in the second case. Second case also includes N:p.A220V;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22227	22227	.	+	.	ID=ID_126;Name=A222V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=739;ao=11;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C665T;aa_name=p.A222V;hgvs_nt=NC_045512.2:g.665C>T;hgvs_aa=YP_009724390.1:p.Ala222Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014666666666666666;function_category=reinfection;source=https://dx.doi.org/10.3390%2Fv13040661;citation=Brehm et al. (2021);comb_mutation=D614G;function_description=27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3). Both cases were mild. Second case also includes N:p.A220V;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22264	22264	.	+	.	ID=ID_127;Name=N234N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=734;ao=16;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C702T;aa_name=p.N234N;hgvs_nt=NC_045512.2:g.702C>T;hgvs_aa=YP_009724390.1:p.Asn234Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22289	22289	.	+	.	ID=ID_128;Name=A243S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=745;ao=5;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G727T;aa_name=p.A243S;hgvs_nt=NC_045512.2:g.727G>T;hgvs_aa=YP_009724390.1:p.Ala243Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22330	22330	.	+	.	ID=ID_129;Name=S256S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=735;ao=6;dp=741;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A768G;aa_name=p.S256S;hgvs_nt=NC_045512.2:g.768A>G;hgvs_aa=YP_009724390.1:p.Ser256Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008097165991902834;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf;citation=Motozono et al. (2021);comb_mutation=;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_110;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=S13I,W152C;function_description=14 of 34 RBD-specific mAbs showed reduced neutralization to the B.1.427/B.1.429 variant pseudotype.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771;citation=Li et al. (2020);comb_mutation=;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_131;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_114;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,W152C;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4];heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_110;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,W152C;function_description=Swab samples N/NP viral RNA is approximately 2-fold higher in B.1.427/B.1.429 than in non-variant viruses.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_131;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_110;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=S13I,W152C;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10 convalescent plasma was somewhat poorer (3.1-fold).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_110;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1.full.pdf;citation=McCallum et al. (2021);comb_mutation=S13I,W152C;function_description=In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for B.1.427/B.1.429 compared to wildtype (D614G). In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_110;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,W152C;function_description=Antibody neutralization assays showed 6.7-fold resistence against 7/8 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_131;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_110;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,W152C;function_description=Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	"ID=ID_110;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1093/cid/ciab283;citation=Peng et al. (2021);comb_mutation=S13I,W152C;function_description=Lineages bearing these spike mutations comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household  contacts exposed to the ""California"" or ""West Coast"" variants (B.1.427 and B.1.429) were at higher risk of infection compared  to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, RR;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_131;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_114;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,W152C;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_131;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_110;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=S13I,W152C;function_description=Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was reduced ~2.8-fold compared to wildtype (D614G) S.  It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose).  Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech BNT162b2-elicited plasma neutralizing activity.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_114;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=S13I,W152C,D614G;function_description=Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_114;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=S13I,W152C,D614G;function_description=Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_114;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=S13I,W152C,D614G;function_description=Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_114;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,W152C,D614G;function_description=6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_130;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_131;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_114;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,W152C;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23155	23155	.	+	.	ID=ID_132;Name=T531T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=626;ao=123;dp=749;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T1593C;aa_name=p.T531T;hgvs_nt=NC_045512.2:g.1593T>C;hgvs_aa=YP_009724390.1:p.Thr531Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.16421895861148197;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23383	23383	.	+	.	ID=ID_133;Name=Q607H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=738;ao=12;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G1821T;aa_name=p.Q607H;hgvs_nt=NC_045512.2:g.1821G>T;hgvs_aa=YP_009724390.1:p.Gln607His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_116;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P26S;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_120;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D138Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_109;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_113;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.42x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_124;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=W152C;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_114;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_116;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P26S;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_120;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D138Y;function_description=1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_109;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_113;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_124;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=W152C;function_description=1.15x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_114;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_114;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_114;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=S13I,W152C,L452R;function_description=Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_114;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_114;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_126;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=humoral response durability;source=https://dx.doi.org/10.3390%2Fv13040661;citation=Brehm et al. (2021);comb_mutation=A222V;function_description=27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3), i.e. with a  9 month interval. Both cases were mild. No significant differences in the neutralizing capacity of the two linages were observed in 4 sera taken (1 pre-reinfection,  three post-reinfection). Neutralizing antibody titres (IC50) before and immediately after re-infection were <300 against  both strains, and jumped >7x upon re-infection. Viral titres were also higher in the second case. Second case also includes N:p.A220V;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_134;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_126;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://dx.doi.org/10.3390%2Fv13040661;citation=Brehm et al. (2021);comb_mutation=A222V;function_description=27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3). Both cases were mild. Second case also includes N:p.A220V;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_116;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P26S;function_description=1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_120;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D138Y;function_description=1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_109;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_113;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_124;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=W152C;function_description=1.03x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_114;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23698	23698	.	+	.	ID=ID_135;Name=I712I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=741;ao=6;dp=747;sample_size=777;Reference_seq=T;Variant_seq=A;nt_name=g.T2136A;aa_name=p.I712I;hgvs_nt=NC_045512.2:g.2136T>A;hgvs_aa=YP_009724390.1:p.Ile712Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008032128514056224;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23897	23897	.	+	.	ID=ID_136;Name=Q779E;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=731;ao=16;dp=747;sample_size=777;Reference_seq=C;Variant_seq=G;nt_name=g.C2335G;aa_name=p.Q779E;hgvs_nt=NC_045512.2:g.2335C>G;hgvs_aa=YP_009724390.1:p.Gln779Glu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0214190093708166;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24023	24023	.	+	.	ID=ID_137;Name=L821L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=637;ao=110;dp=747;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C2461T;aa_name=p.L821L;hgvs_nt=NC_045512.2:g.2461C>T;hgvs_aa=YP_009724390.1:p.Leu821Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.14725568942436412;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24069	24069	.	+	.	ID=ID_138;Name=Q836L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=739;ao=8;dp=747;sample_size=777;Reference_seq=A;Variant_seq=T;nt_name=g.A2507T;aa_name=p.Q836L;hgvs_nt=NC_045512.2:g.2507A>T;hgvs_aa=YP_009724390.1:p.Gln836Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0107095046854083;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24349	24349	.	+	.	ID=ID_139;Name=S929S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=746;dp=746;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T2787C;aa_name=p.S929S;hgvs_nt=NC_045512.2:g.2787T>C;hgvs_aa=YP_009724390.1:p.Ser929Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24621	24621	.	+	.	ID=ID_140;Name=A1020V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=742;ao=4;dp=746;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C3059T;aa_name=p.A1020V;hgvs_nt=NC_045512.2:g.3059C>T;hgvs_aa=YP_009724390.1:p.Ala1020Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005361930294906166;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24757	24757	.	+	.	ID=ID_141;Name=V1065V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G3195T;aa_name=p.V1065V;hgvs_nt=NC_045512.2:g.3195G>T;hgvs_aa=YP_009724390.1:p.Val1065Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24892	24892	.	+	.	ID=ID_142;Name=Y1110Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=742;ao=8;dp=750;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T3330C;aa_name=p.Y1110Y;hgvs_nt=NC_045512.2:g.3330T>C;hgvs_aa=YP_009724390.1:p.Tyr1110Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010666666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25473	25473	.	+	.	ID=ID_143;Name=D27D;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=698;ao=52;dp=750;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T81C;aa_name=p.D27D;hgvs_nt=NC_045512.2:g.81T>C;hgvs_aa=YP_009724391.1:p.Asp27Asp;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06933333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25487	25487	.	+	.	ID=ID_144;Name=T32I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=738;ao=12;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C95T;aa_name=p.T32I;hgvs_nt=NC_045512.2:g.95C>T;hgvs_aa=YP_009724391.1:p.Thr32Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25546	25546	.	+	.	ID=ID_145;Name=L52F;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=699;ao=51;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C154T;aa_name=p.L52F;hgvs_nt=NC_045512.2:g.154C>T;hgvs_aa=YP_009724391.1:p.Leu52Phe;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.068;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25553	25553	.	+	.	ID=ID_146;Name=A54V;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=745;ao=5;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C161T;aa_name=p.A54V;hgvs_nt=NC_045512.2:g.161C>T;hgvs_aa=YP_009724391.1:p.Ala54Val;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25563	25563	.	+	.	ID=ID_147;Name=Q57H;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G171T;aa_name=p.Q57H;hgvs_nt=NC_045512.2:g.171G>T;hgvs_aa=YP_009724391.1:p.Gln57His;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25593	25593	.	+	.	ID=ID_148;Name=K67N;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=741;ao=9;dp=750;sample_size=777;Reference_seq=G;Variant_seq=C;nt_name=g.G201C;aa_name=p.K67N;hgvs_nt=NC_045512.2:g.201G>C;hgvs_aa=YP_009724391.1:p.Lys67Asn;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25660	25660	.	+	.	ID=ID_149;Name=V90F;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G268T;aa_name=p.V90F;hgvs_nt=NC_045512.2:g.268G>T;hgvs_aa=YP_009724391.1:p.Val90Phe;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25711	25711	.	+	.	ID=ID_150;Name=Y107H;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T319C;aa_name=p.Y107H;hgvs_nt=NC_045512.2:g.319T>C;hgvs_aa=YP_009724391.1:p.Tyr107His;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25731	25731	.	+	.	ID=ID_151;Name=Y113Y;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=582;ao=167;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C339T;aa_name=p.Y113Y;hgvs_nt=NC_045512.2:g.339C>T;hgvs_aa=YP_009724391.1:p.Tyr113Tyr;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.22296395193591456;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25963	25963	.	+	.	ID=ID_152;Name=E191K;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=738;ao=10;dp=748;sample_size=777;Reference_seq=G;Variant_seq=A;nt_name=g.G571A;aa_name=p.E191K;hgvs_nt=NC_045512.2:g.571G>A;hgvs_aa=YP_009724391.1:p.Glu191Lys;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013368983957219251;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26042	26042	.	+	.	ID=ID_153;Name=T217I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=744;ao=4;dp=748;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C650T;aa_name=p.T217I;hgvs_nt=NC_045512.2:g.650C>T;hgvs_aa=YP_009724391.1:p.Thr217Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053475935828877;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26198	26198	.	+	.	ID=ID_154;Name=T269M;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=743;ao=5;dp=748;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C806T;aa_name=p.T269M;hgvs_nt=NC_045512.2:g.806C>T;hgvs_aa=YP_009724391.1:p.Thr269Met;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0066844919786096255;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26625	26625	.	+	.	ID=ID_155;Name=L35L;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=742;ao=6;dp=748;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C103T;aa_name=p.L35L;hgvs_nt=NC_045512.2:g.103C>T;hgvs_aa=YP_009724393.1:p.Leu35Leu;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008021390374331552;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26681	26681	.	+	.	ID=ID_156;Name=F53F;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=748;dp=748;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C159T;aa_name=p.F53F;hgvs_nt=NC_045512.2:g.159C>T;hgvs_aa=YP_009724393.1:p.Phe53Phe;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27012	27012	.	+	.	ID=ID_157;Name=L164L;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=716;ao=21;dp=737;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C490T;aa_name=p.L164L;hgvs_nt=NC_045512.2:g.490C>T;hgvs_aa=YP_009724393.1:p.Leu164Leu;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.028493894165535955;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27242	27242	.	+	.	ID=ID_158;Name=I14T;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=738;ao=4;dp=742;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T41C;aa_name=p.I14T;hgvs_nt=NC_045512.2:g.41T>C;hgvs_aa=YP_009724394.1:p.Ile14Thr;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005390835579514825;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27263	27263	.	+	.	ID=ID_159;Name=T21I;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=720;ao=21;dp=741;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C62T;aa_name=p.T21I;hgvs_nt=NC_045512.2:g.62C>T;hgvs_aa=YP_009724394.1:p.Thr21Ile;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02834008097165992;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27393	27393	.	+	.	ID=ID_160;Name=g.C-1T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=737;ao=6;dp=743;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C-1T;aa_name=;hgvs_nt=NC_045512.2:g.1C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008075370121130552;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27492	27492	.	+	.	ID=ID_161;Name=E33E;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=738;ao=4;dp=742;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A99G;aa_name=p.E33E;hgvs_nt=NC_045512.2:g.99A>G;hgvs_aa=YP_009724395.1:p.Glu33Glu;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005390835579514825;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27494	27494	.	+	.	ID=ID_162;Name=P34L;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=716;ao=26;dp=742;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C101T;aa_name=p.P34L;hgvs_nt=NC_045512.2:g.101C>T;hgvs_aa=YP_009724395.1:p.Pro34Leu;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03504043126684636;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27503	27503	.	+	.	ID=ID_163;Name=S37F;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=734;ao=8;dp=742;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C110T;aa_name=p.S37F;hgvs_nt=NC_045512.2:g.110C>T;hgvs_aa=YP_009724395.1:p.Ser37Phe;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01078167115902965;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27594	27594	.	+	.	ID=ID_164;Name=C67C;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=735;ao=4;dp=739;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T201C;aa_name=p.C67C;hgvs_nt=NC_045512.2:g.201T>C;hgvs_aa=YP_009724395.1:p.Cys67Cys;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005412719891745603;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27679	27679	.	+	.	ID=ID_165;Name=L96F;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=727;ao=12;dp=739;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C286T;aa_name=p.L96F;hgvs_nt=NC_045512.2:g.286C>T;hgvs_aa=YP_009724395.1:p.Leu96Phe;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016238159675236806;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	27732	27732	.	+	.	ID=ID_166;Name=F114Y;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=695;ao=44;dp=739;sample_size=777;Reference_seq=CTT;Variant_seq=TTA;nt_name=g.CTT339_341TTA;aa_name=p.F114Y;hgvs_nt=n/a;hgvs_aa=YP_009724395.1:p.Phe114Tyr;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05953991880920163;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27762	27762	.	+	.	ID=ID_167;Name=E3X;alias=n/a;gene=ORF7b;protein_name=ORF7b;protein_symbol=ORF7b;protein_id=YP_009725318.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=732;ao=8;dp=740;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G7T;aa_name=p.E3X;hgvs_nt=NC_045512.2:g.7G>T;hgvs_aa=YP_009725318.1:p.Glu3Xaa;hgvs_alias=n/a;vcf_gene=ORF7b;mutation_type=NONSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010810810810810811;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27879	27879	.	+	.	ID=ID_168;Name=H42Y;alias=n/a;gene=ORF7b;protein_name=ORF7b;protein_symbol=ORF7b;protein_id=YP_009725318.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=743;ao=7;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C124T;aa_name=p.H42Y;hgvs_nt=NC_045512.2:g.124C>T;hgvs_aa=YP_009725318.1:p.His42Tyr;hgvs_alias=n/a;vcf_gene=ORF7b;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27890	27890	.	+	.	ID=ID_169;Name=g.G-4T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G-4T;aa_name=;hgvs_nt=NC_045512.2:g.4G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28001	28001	.	+	.	ID=ID_170;Name=P36P;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=723;ao=26;dp=749;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G108T;aa_name=p.P36P;hgvs_nt=NC_045512.2:g.108G>T;hgvs_aa=YP_009724396.1:p.Pro36Pro;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03471295060080107;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28026	28026	.	+	.	ID=ID_171;Name=W45R;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=734;ao=15;dp=749;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T133C;aa_name=p.W45R;hgvs_nt=NC_045512.2:g.133T>C;hgvs_aa=YP_009724396.1:p.Trp45Arg;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.020026702269692925;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28191	28191	.	+	.	ID=ID_172;Name=V100L;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=612;ao=137;dp=749;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G298T;aa_name=p.V100L;hgvs_nt=NC_045512.2:g.298G>T;hgvs_aa=YP_009724396.1:p.Val100Leu;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1829105473965287;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28272	28272	.	+	.	ID=ID_173;Name=g.A-2T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=A;Variant_seq=T;nt_name=g.A-2T;aa_name=;hgvs_nt=NC_045512.2:g.2A>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28280	28280	.	+	.	ID=ID_174;Name=D3Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=256;ao=494;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G7T;aa_name=p.D3Y;hgvs_nt=NC_045512.2:g.7G>T;hgvs_aa=YP_009724397.2:p.Asp3Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6586666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28371	28371	.	+	.	ID=ID_175;Name=S33I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G98T;aa_name=p.S33I;hgvs_nt=NC_045512.2:g.98G>T;hgvs_aa=YP_009724397.2:p.Ser33Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28567	28567	.	+	.	ID=ID_176;Name=D98D;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=743;ao=7;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C294T;aa_name=p.D98D;hgvs_nt=NC_045512.2:g.294C>T;hgvs_aa=YP_009724397.2:p.Asp98Asp;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009333333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28603	28603	.	+	.	ID=ID_177;Name=F110F;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=738;ao=12;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C330T;aa_name=p.F110F;hgvs_nt=NC_045512.2:g.330C>T;hgvs_aa=YP_009724397.2:p.Phe110Phe;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28674	28674	.	+	.	ID=ID_178;Name=A134V;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=745;ao=5;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C401T;aa_name=p.A134V;hgvs_nt=NC_045512.2:g.401C>T;hgvs_aa=YP_009724397.2:p.Ala134Val;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28875	28875	.	+	.	ID=ID_179;Name=S201N;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=746;ao=4;dp=750;sample_size=777;Reference_seq=G;Variant_seq=A;nt_name=g.G602A;aa_name=p.S201N;hgvs_nt=NC_045512.2:g.602G>A;hgvs_aa=YP_009724397.2:p.Ser201Asn;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28877	28877	.	+	.	ID=ID_180;Name=S202G;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=745;ao=5;dp=750;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A604G;aa_name=p.S202G;hgvs_nt=NC_045512.2:g.604A>G;hgvs_aa=YP_009724397.2:p.Ser202Gly;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28887	28887	.	+	.	ID=ID_181;Name=T205I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=750;dp=750;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C614T;aa_name=p.T205I;hgvs_nt=NC_045512.2:g.614C>T;hgvs_aa=YP_009724397.2:p.Thr205Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28975	28975	.	+	.	ID=ID_182;Name=M234I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=613;ao=135;dp=748;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G702T;aa_name=p.M234I;hgvs_nt=NC_045512.2:g.702G>T;hgvs_aa=YP_009724397.2:p.Met234Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1804812834224599;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29257	29257	.	+	.	ID=ID_183;Name=G328G;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=738;ao=11;dp=749;sample_size=777;Reference_seq=A;Variant_seq=G;nt_name=g.A984G;aa_name=p.G328G;hgvs_nt=NC_045512.2:g.984A>G;hgvs_aa=YP_009724397.2:p.Gly328Gly;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014686248331108143;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29362	29362	.	+	.	ID=ID_184;Name=F363F;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=4;ao=743;dp=747;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C1089T;aa_name=p.F363F;hgvs_nt=NC_045512.2:g.1089C>T;hgvs_aa=YP_009724397.2:p.Phe363Phe;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9946452476572959;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29523	29523	.	+	.	ID=ID_185;Name=T417I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=743;ao=6;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C1250T;aa_name=p.T417I;hgvs_nt=NC_045512.2:g.1250C>T;hgvs_aa=YP_009724397.2:p.Thr417Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00801068090787717;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29545	29545	.	+	.	ID=ID_186;Name=g.C-13T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=731;ao=18;dp=749;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C-13T;aa_name=;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02403204272363151;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29595	29595	.	+	.	ID=ID_187;Name=I13T;alias=n/a;gene=ORF10;protein_name=ORF10 protein;protein_symbol=ORF10;protein_id=YP_009725255.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=744;ao=5;dp=749;sample_size=777;Reference_seq=T;Variant_seq=C;nt_name=g.T38C;aa_name=p.I13T;hgvs_nt=NC_045512.2:g.38T>C;hgvs_aa=YP_009725255.1:p.Ile13Thr;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=MISSENSE;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006675567423230975;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29614	29614	.	+	.	ID=ID_188;Name=C19C;alias=n/a;gene=ORF10;protein_name=ORF10 protein;protein_symbol=ORF10;protein_id=YP_009725255.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=737;ao=10;dp=747;sample_size=777;Reference_seq=C;Variant_seq=T;nt_name=g.C57T;aa_name=p.C19C;hgvs_nt=NC_045512.2:g.57C>T;hgvs_aa=YP_009725255.1:p.Cys19Cys;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=SILENT;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013386880856760375;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29706	29706	.	+	.	ID=ID_189;Name=g.G29706C;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=718;ao=30;dp=748;sample_size=777;Reference_seq=G;Variant_seq=C;nt_name=g.G29706C;aa_name=;hgvs_nt=NC_045512.2:g.29706G>C;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040106951871657755;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	29748	29748	.	+	.	ID=ID_190;Name=g.TACGATCGAGTGTAC29748T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=721;ao=4;dp=725;sample_size=777;Reference_seq=TACGATCGAGTGTAC;Variant_seq=T;nt_name=g.TACGATCGAGTGTAC29748T;aa_name=;hgvs_nt=n/a;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005517241379310344;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29773	29773	.	+	.	ID=ID_191;Name=g.G29773T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=57;ao=11;dp=68;sample_size=777;Reference_seq=G;Variant_seq=T;nt_name=g.G29773T;aa_name=;hgvs_nt=NC_045512.2:g.29773G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.429;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.16176470588235295;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
